Abstract P61: SURFACEOME PROFILING TO IDENTIFY TARGETABLE CELL SURFACE ANTIGENS IN SOFT TISSUE SARCOMAS

Abstract Soft tissue sarcomas (STS) represent rare cancers originating from mesenchymal tissues, featuring over 70 histological subtypes with diverse genetic defects and clinical outcomes. Current treatment options for STS mainly involve surgical procedures and anthracycline-based chemotherapy, which often prove ineffective across multiple STS subtypes. Consequently, there's a pressing need for novel, STS-specific therapies. Targeting cell surface antigens expressed exclusively in STS has emerged as a promising approach. However, the surfaceome of STS remains largely uncharacterized. In our research, we employed mass spectrometry to analyze biotinylated and immunoprecipitated cell surface proteins expressed in STS cell lines and patient samples. Through this method, we've identified several promising cell surface antigens that could potentially serve as therapeutic targets for STS. Further validation of these antigens across various experimental settings is crucial to confirm their efficacy and pave the way for new strategies in STS treatment. Citation Format: Phuong Mai Hoang, Wai Khang Yong, Dennis Kappei, Anand D. Jeyasekharan. SURFACEOME PROFILING TO IDENTIFY TARGETABLE CELL SURFACE ANTIGENS IN SOFT TISSUE SARCOMAS abstract. In: Proceedings of Frontiers in Cancer Science 2024; 2024 Nov 13-15; Singapore. Philadelphia (PA): AACR; Cancer Res 2025;85 (15Suppl): Abstract nr P61.